CARDIO DIAGNOSTICS HOLDINGS
CDIONASDAQTrading Snapshot
- Day Range
- $1.91 – $1.92
- 52-Week Range
- $0.97 – $7.91
- Volume
- $2.67B
- Avg Volume
- $2.75B
- Shares Outstanding
- 3.0M
- Next Earnings
- Nov 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $14,825
- Last Q Revenue
- $5,360
- P/E Ratio
- —
- P/S Ratio
- 382.7x
- EPS (TTM)
- $-2.92
- Dividend Yield
- —
- Dilution (1yr)
- −96.0%
Why Investors Own CDIO
- ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CARDIO DIAGNOSTICS HOLDINGS
CDIO
StockOtter · stockotter.spaceAbout CARDIO DIAGNOSTICS HOLDINGS
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Shares Shorted: Short Interest Down 77.7% in September
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO - Get Free Report) was the target of a large drop in short interest in September. As of September 15th, there was short interest totaling 5,259 shares, a drop of 77.7% from
Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript
Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis
Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses b
Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
[url="]Cardio Diagnostics Holdings, Inc.[/url] (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edit
Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript
Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.